CN117045705A - 一种凹凸棒石基烫伤膏及其制备方法 - Google Patents
一种凹凸棒石基烫伤膏及其制备方法 Download PDFInfo
- Publication number
- CN117045705A CN117045705A CN202311234356.7A CN202311234356A CN117045705A CN 117045705 A CN117045705 A CN 117045705A CN 202311234356 A CN202311234356 A CN 202311234356A CN 117045705 A CN117045705 A CN 117045705A
- Authority
- CN
- China
- Prior art keywords
- attapulgite
- ointment
- scalding
- parts
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960000892 attapulgite Drugs 0.000 title claims abstract description 54
- 229910052625 palygorskite Inorganic materials 0.000 title claims abstract description 54
- 239000002674 ointment Substances 0.000 title claims abstract description 38
- 206010053615 Thermal burn Diseases 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims description 16
- 239000003814 drug Substances 0.000 claims abstract description 13
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 9
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000009498 luteolin Nutrition 0.000 claims abstract description 9
- 239000000341 volatile oil Substances 0.000 claims abstract description 9
- CUXYLFPMQMFGPL-UHFFFAOYSA-N (9Z,11E,13E)-9,11,13-Octadecatrienoic acid Natural products CCCCC=CC=CC=CCCCCCCCC(O)=O CUXYLFPMQMFGPL-UHFFFAOYSA-N 0.000 claims abstract description 8
- CUXYLFPMQMFGPL-SUTYWZMXSA-N all-trans-octadeca-9,11,13-trienoic acid Chemical compound CCCC\C=C\C=C\C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-SUTYWZMXSA-N 0.000 claims abstract description 8
- 244000178870 Lavandula angustifolia Species 0.000 claims abstract description 7
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims abstract description 7
- 235000001405 Artemisia annua Nutrition 0.000 claims abstract description 5
- 240000000011 Artemisia annua Species 0.000 claims abstract description 5
- 235000015763 Artemisia ludoviciana Nutrition 0.000 claims abstract description 5
- 244000267790 Artemisia ludoviciana Species 0.000 claims abstract description 5
- 241001071917 Lithospermum Species 0.000 claims abstract description 5
- 241000028204 Vincetoxicum atratum Species 0.000 claims abstract description 5
- 239000001102 lavandula vera Substances 0.000 claims abstract description 5
- 235000018219 lavender Nutrition 0.000 claims abstract description 5
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims abstract description 5
- 235000019477 peppermint oil Nutrition 0.000 claims abstract description 5
- 241001301715 Crepidiastrum sonchifolium Species 0.000 claims abstract description 4
- 239000000463 material Substances 0.000 claims abstract description 4
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 16
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000012071 phase Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 12
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 12
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000003921 oil Substances 0.000 claims description 9
- 235000019198 oils Nutrition 0.000 claims description 9
- -1 polydimethylsiloxane Polymers 0.000 claims description 9
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 8
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 8
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 8
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 8
- 229930182478 glucoside Natural products 0.000 claims description 8
- 150000008131 glucosides Chemical class 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 8
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 8
- 229960002216 methylparaben Drugs 0.000 claims description 8
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 8
- 239000004006 olive oil Substances 0.000 claims description 8
- 235000008390 olive oil Nutrition 0.000 claims description 8
- 229960005323 phenoxyethanol Drugs 0.000 claims description 8
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 8
- 229940032094 squalane Drugs 0.000 claims description 8
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 8
- 239000000230 xanthan gum Substances 0.000 claims description 8
- 229920001285 xanthan gum Polymers 0.000 claims description 8
- 229940082509 xanthan gum Drugs 0.000 claims description 8
- 235000010493 xanthan gum Nutrition 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- 229960003415 propylparaben Drugs 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 7
- 229940099259 vaseline Drugs 0.000 claims description 7
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 6
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 6
- 229960000458 allantoin Drugs 0.000 claims description 6
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 6
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 5
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 5
- 229960005150 glycerol Drugs 0.000 claims description 4
- 229940075529 glyceryl stearate Drugs 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000008346 aqueous phase Substances 0.000 claims description 3
- 238000000498 ball milling Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000009210 therapy by ultrasound Methods 0.000 claims description 3
- 238000007598 dipping method Methods 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229940074928 isopropyl myristate Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 208000027418 Wounds and injury Diseases 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 208000032544 Cicatrix Diseases 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 231100000241 scar Toxicity 0.000 abstract description 3
- 230000037387 scars Effects 0.000 abstract description 3
- 208000014674 injury Diseases 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract 1
- 230000003179 granulation Effects 0.000 abstract 1
- 238000005469 granulation Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000001338 necrotic effect Effects 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 12
- 210000002615 epidermis Anatomy 0.000 description 12
- 210000004207 dermis Anatomy 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 230000012010 growth Effects 0.000 description 5
- 210000003780 hair follicle Anatomy 0.000 description 5
- 210000001732 sebaceous gland Anatomy 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000008719 thickening Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种凹凸棒石基烫伤膏。所述凹凸棒石基烫伤膏由酸化凹凸棒石、棕桐酸、木犀草素、紫草、鼠曲草、白薇、白芷、白蒿、山苦荬、薄荷油、薰衣草精油及药用辅料制备得到。本发明烫伤膏具清热解毒、去腐生肌、抗炎症抗感染等多重功效，配方中的多种有效中药组分合理配伍与凹凸棒石、精油等结合协作高效治疗修复烫伤和伤后疤痕，且配方简单、原料易得。
Description
技术领域
本发明属于烫伤膏领域，具体涉及一种凹凸棒石基烫伤膏。
背景技术
烫伤膏是刺激创伤表面，还有周围残留的皮肤，从而促进分裂增生的皮肤。烫伤膏具有局部的杀菌功效，能够营造局部稳定的渗透压，有效的消除创伤，还有镇痛的作用，能够促进自身皮肤的分裂增生和自我修复，是在最大程度上，保持皮肤完整的结构和功能了。烫伤膏因使用方法简单，对轻度烫伤有简易方便的治疗作用而广泛被使用。
发明内容
基于上述现有技术，本发明的目的在于提供一种凹凸棒石基烫伤膏。
本发明实现上述目的所采用的技术方案如下：
一种凹凸棒石基烫伤膏，按重量份数计，所述凹凸棒石基烫伤膏由酸化凹凸棒石10份、棕桐酸0.2~0.5份、木犀草素0.3~1份、紫草2~5份、鼠曲草2~5份、白薇2~5份、白芷2~5份、白蒿2~5份、山苦荬2~5份、薄荷油2~4份、薰衣草精油2~4份，以及药用辅料制备得到。
优选地，所述凹凸棒石基烫伤膏中酸化凹凸棒石的含量为8~10wt%。
上述凹凸棒石基烫伤膏的制备方法，包括以下步骤：
（1）将酸化凹凸棒石、棕桐酸和木犀草素混合，湿法球磨，干燥，得到改性凹凸棒石；
（2）将紫草、鼠曲草、白薇、白芷、白蒿和山苦荬粉碎，加水浸泡，超声，抽滤，得到中药提取液；
（3）配制水相：向中药提取液中加入甘油、尿囊素、黄原胶和羟苯甲酯，加热至80~85℃，得到水相；
（4）配制油相：将鲸蜡硬脂基葡糖苷、甘油硬脂酸酯、鲸蜡硬脂醇、凡士林、橄榄油、聚二甲基硅氧烷、角鲨烷、肉豆蔻酸异丙酯、生育酚乙酸酯、羟苯丙酯和改性凹凸棒石混合加热至80~85℃，得到油相；
（5）将水相加入油相，均质，温度降至50℃后，加入薄荷油、薰衣草精油和苯氧乙醇，均质，得到所述的凹凸棒石基烫伤膏。
优选地，所述酸化凹凸棒石通过以下方法得到：
凹凸棒石先用盐酸进行热浸渍，然后水洗至中性，干燥，得到酸化凹凸棒石。
更优选地，盐酸的浓度为1~2mol/L，热浸渍的温度为70~90℃，时间为5~8小时。
优选地，步骤（2），浸泡的料液比为1:4，浸泡的时间为8~12小时，超声处理的时间为1~2小时。
优选地，凡士林、橄榄油和聚二甲基硅氧烷的总质量与中药提取液的质量之比为1:3~5，更优选地，凡士林、橄榄油、聚二甲基硅氧烷的质量比为2:1:1。
优选地，在所述凹凸棒石基烫伤膏中，甘油、角鲨烷和肉豆蔻酸异丙酯的总含量为2~6wt%，黄原胶和鲸蜡硬脂基葡糖苷的总含量为1~3wt%，甘油硬脂酸酯和鲸蜡硬脂醇的总含量为0.5~2wt%，羟苯甲酯、羟苯丙酯和苯氧乙醇的总含量为0.2~1wt%，尿囊素的含量为0.2~1wt%，生育酚乙酸酯的含量为0.2~1wt%。
更优选地，甘油、角鲨烷和肉豆蔻酸异丙酯的质量比为1~2:1~2:1~2，黄原胶和鲸蜡硬脂基葡糖苷的质量比为1:1~2，甘油硬脂酸酯和鲸蜡硬脂醇的质量比为1:1~2，羟苯甲酯、羟苯丙酯和苯氧乙醇的质量比为1~5:1~5:1~2。
本发明烫伤膏配方中的凹凸棒石具有极强的吸附性，不仅可将中药提取液中的无效成分如蛋白质等直接吸附进其孔道中，从而达到吸附沉淀效果，还能吸附细菌、霉菌及其他异物，而且含有多种微量元素，能刺激和促进创口新生组织的生长，对治疗皮肤溃疡效果很好。除此之外，凹凸棒石优良的平滑性、密合性和通气性为本款烫伤膏起到良效。紫草、鼠曲草、白薇、白芷、白蒿和山苦荬等中药成分起到解毒透疹、活血止痛、抗炎抗菌等功效。薰衣草精油清热解毒，清洁皮肤，还具有可促进受损组织再生恢复等护肤功能，而薄荷油营养价值丰富，具有抗炎、抗氧化、抗菌和抗病毒的药理作用。本发明烫伤膏配方中的多种有效中药组分合理配伍与凹凸棒石、精油等结合协作高效治疗修复烫伤和伤后疤痕，且配方简单、原料易得。
具体实施方式
以下结合实施例对本发明的技术方案做进一步详细说明。
烫伤膏的药用辅料包括：基质：凡士林、橄榄油、聚二甲基硅氧烷，乳化剂：黄原胶、鲸蜡硬脂基葡糖苷（M68），辅助乳化剂：甘油硬脂酸酯、鲸蜡硬脂醇，保湿剂：甘油、角鲨烷、肉豆蔻酸异丙酯，防腐剂：羟苯甲酯、羟苯丙酯、苯氧乙醇，抗过敏剂：尿囊素，抗氧剂：生育酚乙酸酯。
酸化凹凸棒石的制备：称取20.0g的天然凹凸棒石，浸渍在200.0mL，1mol/L的稀盐酸中，80℃恒温水浴加热6h后，进行抽滤，并用二次去离子水洗至滤出液的pH=7，80℃烘干至恒重，得酸化凹凸棒石。
实施例1
本发明的凹凸棒石基烫伤膏采用乳化法制备，具体过程如下：
1、改性凹凸棒石的制备：将10g酸化凹凸棒石加水配置成5%~10%的浆料，加入0.4g棕桐酸和0.6g木犀草素，湿法球磨，蒸发干燥后粉碎成400目粉体。
2、中药提取液的制备：将4g紫草、4g鼠曲草、3g白薇、3g白芷、3g白蒿和3g山苦荬用蒸馏水洗净、切片，烘干后粉碎过300目筛。将粉末用80g蒸馏水浸泡，浸泡10小时左右后将混合物放入超声破壁机超声1h，再使用布氏漏斗抽滤药液，得到(约79g)中药提取液。
3、配制水相：将上述中药提取液加入水相锅，在搅拌下将2g甘油、0.5g尿囊素、1g黄原胶、0.5g羟苯甲酯加入，加热至80~85℃。
4、配制油相：将上述改性凹凸棒石，以及1g鲸蜡硬脂基葡糖苷、0.5g甘油硬脂酸酯、0.5g鲸蜡硬脂醇、10g凡士林、5g橄榄油、5g聚二甲基硅氧烷、1g角鲨烷、1g肉豆蔻酸异丙酯、0.5g生育酚乙酸酯、0.5g羟苯丙酯加入油相锅，加热至80~85℃，搅拌至完全溶解。
5、乳化：将油相加入乳化锅中，开启中速搅拌，再将水相加入其中，开启真空至0.04MPa，开启高速均质3~5min后，慢速搅拌下开始降温。
6、待温度降至50℃时，将提前混合完全的3g薄荷油、3g薰衣草精油、0.2g苯氧乙醇混合物加入，在真空状态搅拌均匀后，降温至45℃，开启高速均质2~3分钟。检测pH值控制在5.5~7.0之间即为合格，得到凹凸棒石基烫伤膏。
烫伤膏对比样品的制备：
对比样品1：烫伤膏的制备过程及条件同上，区别在于上述步骤1改性时，用天然凹凸棒石替代酸化凹凸棒石。
对比样品2：烫伤膏的制备过程及条件同上，区别在于上述步骤1改性时，不使用棕桐酸，该物质的量全部用木犀草素替代。
对比样品3：烫伤膏的制备过程及条件同上，区别在于上述步骤1改性时，不使用木犀草素，该物质的量全部用棕桐酸替代。
对比样品4：烫伤膏的制备过程及条件同上，区别在于直接用酸化凹凸棒石替代上述步骤4中的改性凹凸棒石。
对比样品5：烫伤膏的制备过程及条件同上，区别在于上述步骤4中不添加改性凹凸棒石，即为空白烫伤膏。
对比样品6：市售某知名品牌烫伤膏。
采用本发明的凹凸棒石基烫伤膏及对比样品对已经构建好的小鼠烫伤模型进行药物治疗，共16组（每种药膏各处理两组）：空白（烫伤不处理组）、烫伤后本发明处理组和烫伤后6种对比样品处理组，观察处理14后的烫伤表面，观察结果如表1所示。
表1 小鼠烫伤表面的观察结果
| 序号 | 使用药膏 | 14天效果 |
| 01 | 空 白 | 小鼠皮肤烫伤面观察到许多脱落的表皮组织，细胞严重坏死，表面起伏不平伤痕明显，真皮层与表皮界无界限，真皮层空洞明显，细胞无序排列，几乎无胶原纤维束。 |
| 02 | 本 发 明 | 真皮层与表皮界限分明，毛囊、皮脂腺结构清晰可见，细胞形态生长良好，胶原纤维束增厚较多，表皮恢复到正常水平。 |
| 03 | 对比样品1 | 真皮层与表皮界限较为分明，毛囊、皮脂腺结构有所恢复，细胞形态生长相对较好，胶原纤维束增厚较多，表皮恢复到正常水平50%左右。 |
| 04 | 对比样品2 | 真皮层与表皮界限较为分明，毛囊、皮脂腺结构有所恢复，细胞形态生长相对较好，胶原纤维束增厚较多，表皮恢复到正常水平70%左右。 |
| 05 | 对比样品3 | 真皮层与表皮界限较为分明，毛囊、皮脂腺结构有所恢复，细胞形态生长相对较好，胶原纤维束增厚较多，表皮恢复到正常水平85%左右。 |
| 06 | 对比样品4 | 真皮层与表皮界限区分不明显，毛囊、皮脂腺结构有所恢复，但数量不大，细胞形态生长相对较差，胶原纤维束增厚较少。 |
| 07 | 对比样品5 | 相对于空白组，治疗效果有所改善，但不明显。 |
| 08 | 对比样品6 | 表皮仍有空洞，真皮成较厚，细胞形态较好。 |
最后应说明的是：以上所述仅为本发明的优选实施例而已，并不用于限制本发明，尽管参照前述实施例对本发明进行了详细的说明，对于本领域的技术人员来说，其依然可以对前述各实施例所记载的技术方案进行修改，或者对其中部分技术特征进行等同替换。凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (8)
1.一种凹凸棒石基烫伤膏，其特征在于：按重量份数计，所述凹凸棒石基烫伤膏由酸化凹凸棒石10份、棕桐酸0.2~0.5份、木犀草素0.3~1份、紫草2~5份、鼠曲草2~5份、白薇2~5份、白芷2~5份、白蒿2~5份、山苦荬2~5份、薄荷油2~4份、薰衣草精油2~4份，以及药用辅料制备得到。
2.根据权利要求1所述的凹凸棒石基烫伤膏，其特征在于：所述凹凸棒石基烫伤膏中酸化凹凸棒石的含量为8~10wt%。
3.权利要求1或2所述凹凸棒石基烫伤膏的制备方法，其特征在于：所述制备方法包括以下步骤：
（1）将酸化凹凸棒石、棕桐酸和木犀草素混合，湿法球磨，干燥，得到改性凹凸棒石；
（2）将紫草、鼠曲草、白薇、白芷、白蒿和山苦荬粉碎，加水浸泡，超声，抽滤，得到中药提取液；
（3）配制水相：向中药提取液中加入甘油、尿囊素、黄原胶和羟苯甲酯，加热至80~85℃，得到水相；
（4）配制油相：将鲸蜡硬脂基葡糖苷、甘油硬脂酸酯、鲸蜡硬脂醇、凡士林、橄榄油、聚二甲基硅氧烷、角鲨烷、肉豆蔻酸异丙酯、生育酚乙酸酯、羟苯丙酯和改性凹凸棒石混合加热至80~85℃，得到油相；
（5）将水相加入油相，均质，温度降至50℃后，加入薄荷油、薰衣草精油和苯氧乙醇，均质，得到所述的凹凸棒石基烫伤膏。
4.根据权利要求3所述的制备方法，其特征在于：所述酸化凹凸棒石通过以下方法得到：
凹凸棒石先用盐酸进行热浸渍，然后水洗至中性，干燥，得到酸化凹凸棒石。
5.根据权利要求4所述的制备方法，其特征在于：盐酸的浓度为1~2mol/L，热浸渍的温度为70~90℃，时间为5~8小时。
6.根据权利要求3所述的制备方法，其特征在于：步骤（2），浸泡的料液比为1:4，浸泡的时间为8~12小时，超声处理的时间为1~2小时。
7.根据权利要求3所述的制备方法，其特征在于：凡士林、橄榄油和聚二甲基硅氧烷的总质量与中药提取液的质量之比为1:3~5，
在所述凹凸棒石基烫伤膏中，甘油、角鲨烷和肉豆蔻酸异丙酯的总含量为2~6wt%，黄原胶和鲸蜡硬脂基葡糖苷的总含量为1~3wt%，甘油硬脂酸酯和鲸蜡硬脂醇的总含量为0.5~2wt%，羟苯甲酯、羟苯丙酯和苯氧乙醇的总含量为0.2~1wt%，尿囊素的含量为0.2~1wt%，生育酚乙酸酯的含量为0.2~1wt%。
8.根据权利要求7所述的制备方法，其特征在于：凡士林、橄榄油、聚二甲基硅氧烷的质量比为2:1:1，甘油、角鲨烷和肉豆蔻酸异丙酯的质量比为1~2:1~2:1~2，黄原胶和鲸蜡硬脂基葡糖苷的质量比为1:1~2，甘油硬脂酸酯和鲸蜡硬脂醇的质量比为1:1~2，羟苯甲酯、羟苯丙酯和苯氧乙醇的质量比为1~5:1~5:1~2。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311234356.7A CN117045705A (zh) | 2023-09-24 | 2023-09-24 | 一种凹凸棒石基烫伤膏及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311234356.7A CN117045705A (zh) | 2023-09-24 | 2023-09-24 | 一种凹凸棒石基烫伤膏及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117045705A true CN117045705A (zh) | 2023-11-14 |
Family
ID=88661081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311234356.7A Pending CN117045705A (zh) | 2023-09-24 | 2023-09-24 | 一种凹凸棒石基烫伤膏及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117045705A (zh) |
-
2023
- 2023-09-24 CN CN202311234356.7A patent/CN117045705A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108186711A (zh) | 促进伤口愈合的药物组合物 | |
| CN100455311C (zh) | 一种用于烧、烫伤治疗及祛痘产品的中药组合物及其制备方法 | |
| CN111281966B (zh) | 含地龙蛋白的组合物及其制备方法和应用 | |
| CN109700998B (zh) | 一种复方肌肤损伤再生修复剂及其制备方法 | |
| CN110123953B (zh) | 一种促进术后皮肤修复的冷敷贴及其制备方法 | |
| CN117045705A (zh) | 一种凹凸棒石基烫伤膏及其制备方法 | |
| KR20110139486A (ko) | 꿀 및 봉독을 유효성분으로 함유하는 상처 치유용 피부외용제 조성물 | |
| CN109364290A (zh) | 一种薰衣草精油脂质体液体创可贴及其制备方法 | |
| CN112274548B (zh) | 一种具有愈伤功效的外用组合物及其制备方法和应用 | |
| KR20160036834A (ko) | 생약 성분을 발효시킨 복합 발효 추출물을 포함하는 피부 외용제 조성물 | |
| CN112121146B (zh) | 一种用于皮肤创伤的外用凝胶剂及其制备方法 | |
| KR20220128539A (ko) | 초임계 추출법을 이용한 피뿌리풀 추출물을 포함하는 상처 치료용 조성물 | |
| CN108113916B (zh) | 一种天然修复肽面膜液及其制备方法 | |
| CN110090264A (zh) | 一种组合使用修复疤痕产品配方及使用方法 | |
| CN104983936A (zh) | 一种临床护理上用于治疗三期褥疮的中药膏剂 | |
| CN108853293B (zh) | 治疗痔疮的复配精油及其制备方法和使用方法 | |
| CN118178250A (zh) | 一种皮肤剥脱后修复组合物及其应用 | |
| CN115671167A (zh) | 一种具有祛痘功效的中药组合物、中药制剂及其制备方法和应用 | |
| CN112741863A (zh) | 一种治疗皮肤创伤的药物及其制备方法 | |
| CN105125781A (zh) | 一种治疗iii期压疮的中药凝胶剂及其制备方法 | |
| CN113577245A (zh) | 一种祛疤膏及其制备方法 | |
| CN112336805A (zh) | 一种烫伤油及其制备方法 | |
| CN114984294A (zh) | 一种敷料及其制备方法 | |
| CN111905070A (zh) | 一种用于治疗脚气的中药抑菌液及其制备方法 | |
| CN117503793A (zh) | 牛蒡根多糖在制备治疗烧伤的药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |